Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 7 |
| List of Tables | 6 | 2 |
| List of Figures | 8 | 2 |
| Pediatric Vaccines Market to 2017 - Introduction | 10 | 2 |
| GBI Research Report Guidance | 11 | 1 |
| Pediatric Vaccines Market to 2017 - Market Overview | 12 | 3 |
| Vaccine Preventable Diseases | 12 | 1 |
| Vaccine Manufacturing Process | 13 | 1 |
| Determinants of Immunization Coverage | 13 | 1 |
| Immunization Programs | 13 | 1 |
| Public Private Partnerships | 14 | 1 |
| Production Capacity | 14 | 1 |
| Reimbursements | 14 | 1 |
| Pediatric Vaccines Market to 2017 - Global Vaccine Market | 15 | 7 |
| Market Forecasts | 15 | 1 |
| Market Share by Disease Sector | 16 | 1 |
| Market Share by Geography | 17 | 1 |
| Average Cost of Vaccination per Child | 17 | 1 |
| Target Population | 18 | 1 |
| Immunization Coverage | 19 | 1 |
| Drivers and Barriers of the Pediatric Vaccines Market | 20 | 1 |
| Drivers for Pediatric Vaccine Market | 20 | 1 |
| Continuous Growth will be Driven by Combination Vaccines | 20 | 1 |
| Innovation and Growth will be Driven by the Availability of Vaccine Technologies that will Help in Increasing Efficacy and Safety | 20 | 1 |
| Targeting New Diseases will Boost the Growth of the Pediatric Vaccine Market | 21 | 1 |
| Barriers for Pediatric Vaccines Market | 21 | 1 |
| Delays in Realization of Potential due to Limitations in Production Capacity | 21 | 1 |
| Technical Expertise and High Initial Capital Investments Acts as a Huge Entry Barrier | 21 | 1 |
| Delayed Vaccine Launch and Acceptance is Due to the Lack of Harmonized Regulations | 21 | 1 |
| Global Pediatric Vaccines Market to 2017 - Geographical Landscape | 22 | 21 |
| The US | 22 | 1 |
| Market Overview | 22 | 1 |
| Market Forecasts | 22 | 1 |
| Average Cost of Vaccination | 23 | 2 |
| Immunization Coverage | 25 | 1 |
| Immunization Schedule | 26 | 1 |
| Regulatory Framework | 27 | 1 |
| Vaccine Procurement | 28 | 1 |
| Top Five Countries of Europe | 29 | 1 |
| Market Overview | 29 | 1 |
| Market Forecasts | 29 | 1 |
| Average Cost of Vaccination per Child | 30 | 2 |
| Immunization Coverage | 32 | 1 |
| The UK | 33 | 1 |
| France | 34 | 1 |
| Germany | 35 | 1 |
| Italy | 36 | 1 |
| Spain | 37 | 1 |
| Rest of the World | 38 | 1 |
| Market Overview | 38 | 1 |
| Market Forecasts | 38 | 1 |
| Average Cost of Vaccination per Child | 39 | 2 |
| Immunization Coverage | 41 | 1 |
| Immunization Schedule | 42 | 1 |
| Regulatory Framework | 42 | 1 |
| Vaccine Procurement | 42 | 1 |
| Global Pediatric Vaccines Market to 2017 - Therapeutic Landscape | 43 | 31 |
| Hepatitis A | 43 | 1 |
| Overview | 43 | 1 |
| Market Forecasts | 43 | 1 |
| Average Cost of Vaccination | 44 | 1 |
| Target Population | 45 | 1 |
| Marketed Products for Hepatitis A | 46 | 1 |
| Twinrix | 46 | 1 |
| Havrix | 46 | 1 |
| Vaqta | 47 | 1 |
| Ambirix | 47 | 1 |
| Avaxim | 48 | 1 |
| Hepatitis B | 48 | 1 |
| Overview | 48 | 1 |
| Market Forecasts | 49 | 1 |
| Average Cost of Vaccination | 50 | 1 |
| Target Population | 51 | 1 |
| Marketed Products for Hepatitis B | 52 | 1 |
| Recombivax HB | 52 | 1 |
| Engerix-B | 52 | 1 |
| Twinrix | 53 | 1 |
| Comvax | 53 | 1 |
| Pediarix | 54 | 1 |
| Polio | 55 | 1 |
| Overview | 55 | 1 |
| Market Forecasts | 55 | 1 |
| Average Cost of Vaccination | 56 | 1 |
| Target Population | 57 | 1 |
| Marketed Products for Polio | 58 | 1 |
| Ipol | 58 | 1 |
| Pediarix | 58 | 1 |
| Rotavirus | 59 | 1 |
| Overview | 59 | 1 |
| Market Forecasts | 59 | 1 |
| Average Cost of Vaccination | 60 | 1 |
| Target Population | 61 | 1 |
| Immunization Coverage | 61 | 1 |
| Product Analysis | 62 | 1 |
| Marketed Products for Rotavirus | 62 | 1 |
| Rotateq | 62 | 1 |
| Rotarix | 63 | 1 |
| DTaP | 64 | 1 |
| Overview | 64 | 1 |
| Market Forecasts | 64 | 1 |
| Average Cost of Vaccination | 65 | 1 |
| Target Population | 66 | 1 |
| Marketed Products for DTaP | 67 | 1 |
| Tripedia | 67 | 1 |
| Daptacel | 67 | 1 |
| Pentacel | 68 | 1 |
| MMR | 69 | 1 |
| Overview | 69 | 1 |
| Market Forecasts | 69 | 1 |
| Average Cost of Vaccination | 70 | 1 |
| Target Population | 71 | 1 |
| Marketed Products for MMR | 72 | 1 |
| MMR II | 72 | 1 |
| ProQuad | 72 | 2 |
| Global Pediatric Vaccines Market to 2017 - Product Pipeline Analysis | 74 | 20 |
| Research and Development Pipeline by Phase | 74 | 1 |
| Research and Development Pipeline by Indication | 75 | 1 |
| Research and Development Pipeline - Hepatitis A Vaccines | 76 | 1 |
| Overview | 76 | 1 |
| Pipeline by Clinical Phases of Development | 77 | 1 |
| Preclinical | 77 | 1 |
| Phase III | 77 | 1 |
| Research and Development Pipeline - Hepatitis B Vaccines | 77 | 1 |
| Overview | 77 | 1 |
| Pipeline by Clinical Phases of Development | 78 | 1 |
| Preclinical | 78 | 1 |
| Phase I | 79 | 1 |
| Phase II | 80 | 2 |
| Phase III | 82 | 1 |
| NDA Filed | 83 | 1 |
| Research and Development Pipeline - Polio Vaccines | 83 | 1 |
| Overview | 83 | 1 |
| Pipeline by Clinical Phases of Development | 84 | 1 |
| Phase II | 84 | 1 |
| Phase III | 85 | 1 |
| Research and Development Pipeline - Rotavirus Vaccines | 86 | 1 |
| Overview | 86 | 1 |
| Pipeline by Clinical Phases of Development | 86 | 1 |
| Preclinical | 86 | 1 |
| Phase I | 87 | 1 |
| Phase II | 87 | 1 |
| Phase III | 87 | 1 |
| Research and Development Pipeline - DTaP Vaccines | 88 | 1 |
| Overview | 88 | 1 |
| Pipeline by Clinical Phases of Development | 89 | 1 |
| Preclinical | 89 | 1 |
| Phase I | 89 | 1 |
| Phase II | 90 | 1 |
| Phase III | 91 | 1 |
| NDA Filed | 91 | 1 |
| Research and Development Pipeline - MMR Vaccines | 92 | 1 |
| Overview | 92 | 1 |
| Pipeline by Clinical Phases of Development | 92 | 1 |
| Preclinical | 92 | 1 |
| Phase II | 93 | 1 |
| Phase III | 93 | 1 |
| Global Pediatric Vaccines Market - Competitive Landscape | 94 | 8 |
| Overview | 94 | 1 |
| Company Profiling | 94 | 1 |
| Novartis | 94 | 1 |
| Overview | 95 | 1 |
| SWOT Analysis | 95 | 1 |
| GlaxoSmithKline (GSK) | 96 | 1 |
| Overview | 96 | 1 |
| SWOT Analysis | 97 | 1 |
| Sanofi Pasteur MSD | 97 | 1 |
| Overview | 98 | 1 |
| SWOT Analysis | 98 | 1 |
| Merck | 99 | 1 |
| Overview | 99 | 1 |
| SWOT Analysis | 100 | 1 |
| Pfizer | 100 | 1 |
| Overview | 101 | 1 |
| SWOT Analysis | 101 | 1 |
| Global Pediatric Vaccines Market to 2017 - Strategic Consolidations | 102 | 20 |
| Segmentation by Type | 102 | 1 |
| Segmentation by Year | 103 | 1 |
| Mergers and Acquisitions | 104 | 1 |
| Overview | 104 | 1 |
| M&A Deals by Indication | 105 | 1 |
| M&A Deals by Year | 106 | 1 |
| M&A Deals by Geography | 107 | 1 |
| M&A Deals by Value | 108 | 1 |
| Major Mergers and Acquisitions (M&A) | 109 | 1 |
| Sanofi Acquires Majority Stake in Shantha Biotechnics | 109 | 1 |
| Teva Pharmaceutical Industries Completes Acquisition of Ratiopharm | 109 | 1 |
| Johnson &Johnson Acquires Crucell | 110 | 1 |
| Licensing Agreements | 110 | 1 |
| Overview | 110 | 1 |
| Licensing Agreements by Indication | 110 | 2 |
| Licensing Agreements by Year | 112 | 1 |
| Licensing Agreements by Geography | 113 | 1 |
| Licensing Agreements by Value | 114 | 1 |
| Major Licensing Agreements | 115 | 1 |
| Anadys Pharmaceuticals Enters into Licensing Agreement with Novartis | 116 | 1 |
| Schering-Plough Signs Licensing Agreement with Valeant Pharmaceuticals and Metabasis Therapeutics for Pradefovir | 116 | 1 |
| Merck Enters into Licensing Agreement with Dynavax Technologies | 116 | 1 |
| Ligand Enters Into Licensing Agreement with Chiva for Pradefovir and MB01733 | 116 | 1 |
| Co-Development Deals | 117 | 1 |
| Overview | 117 | 1 |
| Co-Development Deals by Indication | 117 | 1 |
| Co-Development Deals by Year | 118 | 1 |
| Co-Development Deals by Geography | 119 | 1 |
| Major Co-Development Deals | 120 | 1 |
| LIDQO Enters Into Co-Development Agreement with MedinCell | 120 | 1 |
| MSD Wellcome Trust Hilleman Enters into Co-Development Agreement with Medicine In Need | 120 | 1 |
| Roche Diagnostics Enters into Research Agreement with Vall d Hebron Institute, CIBE-Rehd and Advanced Biological Laboratories | 121 | 1 |
| iOWH Enters into Research Agreement with Anacor Pharmaceuticals | 121 | 1 |
| Global Pediatric Vaccines Market to 2017 - Appendix | 122 | 6 |
| Market Definitions | 122 | 1 |
| Abbreviations | 122 | 1 |
| Research Methodology | 123 | 4 |
| Global Pediatric Vaccines Market | 123 | 1 |
| Coverage | 123 | 1 |
| Sources of Coverage | 123 | 1 |
| Methodology | 124 | 1 |
| Geographical Landscape | 124 | 1 |
| Coverage | 124 | 1 |
| Sources of Coverage | 124 | 1 |
| Methodology | 124 | 1 |
| Therapeutic Landscape | 125 | 1 |
| Coverage | 125 | 1 |
| Sources of Coverage | 125 | 1 |
| Methodology | 125 | 1 |
| Competitive Landscape | 125 | 1 |
| Coverage | 125 | 1 |
| Sources of Coverage | 125 | 1 |
| Methodology | 125 | 1 |
| Pipeline Analysis | 126 | 1 |
| Coverage | 126 | 1 |
| Sources of Coverage | 126 | 1 |
| Methodology | 126 | 1 |
| Strategic Consolidations | 126 | 1 |
| Coverage | 126 | 1 |
| Sources of Coverage | 126 | 1 |
| Methodology | 126 | 1 |
| Contact Us | 126 | 1 |
| Disclaimer | 126 | 1 |
| Sources | 127 | 1 |
